基本信息
浏览量:2
职业迁徙
个人简介
Andre Strydom is a specialist in the Psychiatry of Intellectual disabilities. Dr. Strydom's research has a specific focus on conditions associated with ageing in intellectual disability (ID) populations, such as Alzheimer's disease in individuals with Down Syndrome (DS). He is an expert in ageing-related issues and the cognitive phenotype(s) associated with trisomy 21.
Current projects and collaborations include the LonDownS consortium previously funded by the Wellcome Trust and currently funded by the MRC to study the development of Alzheimer's Disease in Down syndrome; other funders include the Baily Thomas Fund and the LeJeune Foundation. This work concerns detailed cognitive phenotyping of individuals with Down across the lifespan, and tracking change with ageing using MR, EEG and fNIRS neuroimaging, as well as collecting DNA, blood and cellular samples. His research includes identification of plasma biomarkers of cognitive decline including markers related to inflammation, amyloid processing, and oxidative stress. He is a founding member of the Horizon21 European clinical trial network for Alzheimer’s disease in Down syndrome.
Dr Strydom is also involved in developing and testing the efficacy of medication and complex interventions for the treatment of mental disorders in adults with intellectual disabilities and he leads the Neurodevelopmental disorders clinical trials centre (ND-CTC) in the FANS department which conducts phase II/III clinical trials for treatments of Autism, Down syndrome and other conditions.
He has been an investigator on industry sponsored trials of new drug treatment options in Down syndrome and fragile X syndrome.
Research Interests
Down syndrome
Alzheimer’s disease
Intellectual disabilities
Autism
Current projects and collaborations include the LonDownS consortium previously funded by the Wellcome Trust and currently funded by the MRC to study the development of Alzheimer's Disease in Down syndrome; other funders include the Baily Thomas Fund and the LeJeune Foundation. This work concerns detailed cognitive phenotyping of individuals with Down across the lifespan, and tracking change with ageing using MR, EEG and fNIRS neuroimaging, as well as collecting DNA, blood and cellular samples. His research includes identification of plasma biomarkers of cognitive decline including markers related to inflammation, amyloid processing, and oxidative stress. He is a founding member of the Horizon21 European clinical trial network for Alzheimer’s disease in Down syndrome.
Dr Strydom is also involved in developing and testing the efficacy of medication and complex interventions for the treatment of mental disorders in adults with intellectual disabilities and he leads the Neurodevelopmental disorders clinical trials centre (ND-CTC) in the FANS department which conducts phase II/III clinical trials for treatments of Autism, Down syndrome and other conditions.
He has been an investigator on industry sponsored trials of new drug treatment options in Down syndrome and fragile X syndrome.
Research Interests
Down syndrome
Alzheimer’s disease
Intellectual disabilities
Autism
研究兴趣
论文共 307 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORINGno. 1 (2024): e12563-e12563
Hampus Hillerstrom, Richard Fisher,Matthew P Janicki,Brian Chicoine,Bradley T Christian,Anna Esbensen, Lucille Esralew,Juan Fortea,Sigan Hartley,Jason Hassenstab,Seth M Keller,Sharon Krinsky-McHale,
Alzheimer's & dementia : the journal of the Alzheimer's Association (2024)
ALZHEIMERS & DEMENTIA (2024)
EBioMedicine (2023): 104692-104692
Alzheimer's & Dementiano. 11 (2023): 102766-5137
Cerebral cortex (New York, N.Y. : 1991)no. 16 (2023): 9639-9651
Delia Bishara, Sahar Riaz,Justin Sauer,Christoph Mueller,Siobhan Gee,David Taylor, Robyn-Jenia Wilcha,Millie Edwards,Nirja Beehuspoteea, Anne Marie Bonnici Mallia,Jennifer Brook,Bharathi Balasundaram,
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn